Zilucoplan®

DRUG2 trials

Sponsors

University Hospital, Ghent, Miriam Freimer

Conditions

COVID-19Generalized Myasthenia Gravis (gMG)

Phase 2

Zilucoplan® in Improving Oxygenation, Short-, Longterm Outcome of COVID19 Patients With Acute Hypoxic Respiratory Failure

CompletedNCT04382755

University Hospital, GhentCOVID-19

Start: 2020-05-22End: 2021-04-09Updated: 2023-09-14

Phase 3

Zilucoplan for Severe gMG Exacerbations

RecruitingNCT07215949

Miriam FreimerGeneralized Myasthenia Gravis (gMG)

Start: 2026-01-20End: 2028-04-01Target: 15Updated: 2026-08-28

Related Papers

C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19

Blood Advances2021-12-0164 citations

Zilucoplan in patients with acute hypoxic respiratory failure due to COVID-19 (ZILU-COV): A structured summary of a study protocol for a randomised controlled trial.

2020-11-1913 citations

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial.

2020-09-28149 citations